Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 39 clinical trials
GFR 4 CAR T Cells in MTC Patients

-stimulatory domains (referred to as "CART-GFRa4 cells") in patients with incurable medullary thyroid cancer (MTC).

  • 0 views
  • 04 Sep, 2021
  • 1 location
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control

refractory acute myeloid leukemia (aml)
serum bilirubin level
mitoxantrone
secondary acute myeloid leukemia
  • 15 views
  • 07 Nov, 2020
  • 1 location
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

(VEGFR1-3), RET, AXL, FLT3 and KIT. Cabozantinib has been approved by the FDA for clinical treatment of progressive, metastatic medullary thyroid cancer. Recently published trials have demonstrated

platinum-based chemotherapy
advanced urothelial carcinoma
serum pregnancy test
neutrophil count
transitional cell carcinoma
  • 46 views
  • 22 Sep, 2021
  • 12 locations
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease

electrolytes
progressive disease
metastasis
cancer
vandetanib
  • 18 views
  • 22 Sep, 2021
  • 226 locations
A Study of LOXO-292 in Participants With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation

systemic therapy
kidney function test
solid tumour
cancer
ret inhibitor
  • 1244 views
  • 23 Sep, 2021
  • 161 locations
Phase 1/2 Study of the Highly-selective RET Inhibitor Pralsetinib (BLU-667) in Patients With Thyroid Cancer Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.

lung cancer
cytotoxic chemotherapy
solid tumour
systemic therapy
solid neoplasm
  • 1632 views
  • 09 Sep, 2021
  • 93 locations
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.

metastasis
measurable disease
renal function
RET
cns tumor
  • 29 views
  • 22 Sep, 2021
  • 33 locations
A Phase II Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

): Renal medullary carcinoma (RMC) Cohort 5 (Closed for enrollment): Epithelioid sarcoma (ES) Cohort 6 (Opened for enrollment): Epithelioid sarcoma (ES) undergoing mandatory tumor biopsy

solid tumour
monoclonal antibodies
malignant peripheral nerve sheath tumor
kidney function tests
beta human chorionic gonadotropin
  • 2 views
  • 19 Aug, 2021
  • 25 locations
18F-DOPA II - PET Imaging Optimization

A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: Pediatric patients (less than 18 years old) with congenital hyperinsulinism. Pediatric patients (less than 18 years old) with neuroblastoma. Pediatric (less than 18 years old) or Adult patients (18 or older) with …

  • 0 views
  • 29 Apr, 2021
  • 1 location
  • 0 views
  • 02 Aug, 2021
  • 13 locations